RxDoctor Payments Data

Brittany Davidson, APRN

Family · Owensboro, KYNPI 1043754815

Payments from drug & device makers

$7,896in general payments, 2019–2025

Across 516 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Boston Scientific$1K
  • Ardelyx, Inc.$430
  • Johnson & Johnson$326
  • Takeda Pharmaceuticals U.S.A., Inc.$296
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$79610%
  • Food & beverage$7,10090%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,896 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$42,294
Medicare patients
350
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab17$141,599
LinzessLinaclotide191$125,841
IbsrelaTenapanor Hcl49$90,774
XifaxanRifaximin23$58,378
MovantikNaloxegol Oxalate42$22,250
TrulancePlecanatide21$20,807
Dexlansoprazole DrDexlansoprazole56$15,514
MotegrityPrucalopride Succinate19$14,104
Sucralfate90$7,502
Colestipol Hcl141$7,056
Pantoprazole Sodium501$6,010
Famotidine488$4,937
Budesonide DrBudesonide16$3,972
Ursodiol39$3,925
Omeprazole254$2,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,784$125,841191 claims
Ardelyx, Inc.Ibsrela$430$90,77449 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,330$79,18544 claims
Redhill Biopharma Inc.Movantik$41$22,25042 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$296$14,10419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →